Doceree has introduced Semmelweis, an AI model tailored for pharmaceutical marketing, which emphasizes clinical context over general-purpose AI approaches.
Semmelweis is designed to enhance pharmaceutical commercialization by utilizing Clinical Intent Signals (CIS) that reflect treatment pathways and prescribing behaviors. This model is integrated into Doceree's Daily Command, a commercial operating system aimed at streamlining pharma marketing processes. By leveraging a unique identity graph of over six million verified healthcare providers and numerous electronic health record integrations, Semmelweis aims to identify early prescribing signals while adhering to industry compliance standards.
Unlike typical AI models, Semmelweis operates within a bounded action space, ensuring it does not access patient data and only works with de-identified healthcare provider information. The model's outputs are characterized as advisory and are designed for medical, legal, and regulatory review. Additionally, it features a closed measurement loop that allows for continuous improvement of its recommendations based on observed outcomes.
As pharmaceutical companies increasingly invest in AI for commercial operations, Semmelweis represents a strategic shift towards models that can navigate regulatory frameworks from the outset. This aligns with broader industry trends, as seen in initiatives by major players like Pfizer, which are leveraging AI to enhance productivity and accelerate innovation across various functions. The focus is shifting towards specialized AI solutions that comply with legal and medical standards, indicating a significant evolution in the sector's approach to AI integration.